Lv1
16 积分 2026-01-29 加入
In Vivo CAR T-Cell Therapy Spurs 100% ORR in Phase I
2天前
已完结
Current understanding and management of CAR T cell-associated toxicities
3天前
已完结
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study
9天前
已完结
Response‐adapted chimeric antigen receptor T cell (CAR‐T)–sparing consolidation radiotherapy in high‐risk large B‐cell lymphoma (LBCL): Results of the prospective RESTART protocol
9天前
已完结
A guide to CAR T cell therapies: development, current status and future prospects
17天前
已完结
ASCT, CAR T-cell, or Combined Consolidation for R/R PCNSL in Re-achieved CR: An Inverse Probability of Treatment Weighting-Adjusted Comparative Study
17天前
已完结
A Comparison of 3-Year Follow-up of ZUMA-5 (Axicabtagene Ciloleucel) With SCHOLAR-5 in Relapsed/Refractory Follicular Lymphoma
25天前
已完结
Effectiveness of CAR-T Cell Therapies for Relapsed/Refractory Follicular Lymphoma: An External Control Arm Study
25天前
已完结
Comparing apples and oranges: The ZUMA‐7, TRANSFORM and BELINDA trials
25天前
已完结
Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large B Cell Lymphoma
25天前
已完结
皖公网安备34019202002308
